**RESEARCH ARTICLE** 

# Risk factors for surgical site infection in patients undergoing colorectal surgery: A meta-analysis of observational studies

ZhaoHui Xu<sup>1,2</sup>, Hui Qu<sup>1,2</sup>, ZeZhong Gong<sup>1,2</sup>, George Kanani<sup>1,2</sup>, Fan Zhang<sup>1</sup>, YanYing Ren<sup>1</sup>, Shuai Shao<sup>1</sup>, XiaoLiang Chen<sup>1</sup>, Xin Chen<sup>1</sup>\*

1 Department of Hernia and Colorectal Surgery, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China, 2 Dalian Medical University, Dalian, China

\* chenxincjz@gmail.com

# Abstract

# Objective

Surgical site infection (SSI) is the second most prevalent hospital-based infection and affects the surgical therapeutic outcomes. However, the factors of SSI are not uniform. The main purpose of this study was to understand the risk factors for the different types of SSI in patients undergoing colorectal surgery (CRS).

# Methods

PubMed, EMBASE, and Cochrane Library databases were searched using the relevant search terms. The data extraction was independently performed by two investigators using a standardized format, following the pre-agreed criteria. Meta-analysis for the risk factors of SSI in CRS patients was carried out using Review Manager 5.3 (RevMan 5.3) and Stata 15.1 software. The quality of evidence was evaluated using total sample size, Egger's *P*-value, and intergroup heterogeneity, which contained three levels: high-quality (Class I), moderate-quality (Class II/III), and low-quality (Class IV). The publication bias of the included studies was assessed using funnel plots, Begg's test, and Egger's test.

# Results

Of the 2660 potentially eligible studies, a total of 31 studies (22 retrospective and 9 prospective cohort studies) were included in the final analysis. Eventually, the high-quality evidence confirmed that SSI was correlated with obesity (RR = 1.60, 95% confidence interval (CI): 1.47–1.74), ASA score  $\geq$ 3 (RR = 1.34, 95% CI: 1.19–1.51), and emergent surgery (RR = 1.36, 95% CI: 1.19–1.55). The moderate-quality evidence showed the correlation of SSI with male sex (RR = 1.30, 95% CI: 1.14–1.49), diabetes mellitus (RR = 1.65, 95% CI: 1.24–2.20), inflammatory bowel disease (RR = 2.12, 95% CI: 1.24–3.61), wound classification >2 (RR = 2.65, 95% CI: 1.52–4.61), surgery duration  $\geq$ 180 min (RR = 1.88, 95% CI: 1.49–2.36), cigarette smoking (RR = 1.38, 95% CI: 1.14–1.67), open surgery (RR = 1.81, 95% CI: 1.57–2.10), stoma formation (RR = 1.89, 95% CI: 1.28–2.78), and blood transfusion



# G OPEN ACCESS

**Citation:** Xu Z, Qu H, Gong Z, Kanani G, Zhang F, Ren Y, et al. (2021) Risk factors for surgical site infection in patients undergoing colorectal surgery: A meta-analysis of observational studies. PLoS ONE 16(10): e0259107. https://doi.org/10.1371/ journal.pone.0259107

Editor: Zubing Mei, Shuguang Hospital, CHINA

Received: April 27, 2021

Accepted: October 12, 2021

Published: October 28, 2021

**Copyright:** © 2021 Xu et al. This is an open access article distributed under the terms of the <u>Creative</u> <u>Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting information files.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

(RR = 2.03, 95% CI:1.34–3.06). Moderate-quality evidence suggested no association with respiratory comorbidity (RR = 2.62, 95% CI:0.84–8.13) and neoplasm (RR = 1.24, 95% CI:0.58–2.26). Meanwhile, the moderate-quality evidence showed that the obesity (RR = 1.28, 95% CI: 1.24–1.32) and blood transfusion (RR = 2.32, 95% CI: 1.26–4.29) were independent risk factors for organ/space SSI (OS-SSI). The high-quality evidence showed that no correlation of OS-SSI with ASA score  $\geq$ 3 and stoma formation. Furthermore, the moderate-quality evidence showed that no association of OS-SSI with open surgery (RR = 1.37, 95% CI: 0.62–3.04). The high-quality evidence demonstrated that I-SSI was correlated with stoma formation (RR = 2.55, 95% CI: 1.87–3.47). There were some certain publication bias in 2 parameters based on asymmetric graphs, including diabetes mellitus and wound classification >2. The situation was corrected using the trim and fill method.

## Conclusions

The understanding of these factors might make it possible to detect and treat the different types of SSI more effectively in the earlier phase and might even improve the patient's clinical prognosis. Evidence should be continuously followed up and updated, eliminating the potential publication bias. In the future, additional high-level evidence is required to verify these findings.

# Introduction

Surgical site infection (SSI), which might be either at the site of incision (superficial incisional SSI (SSSI) or deep incisional SSI (DSSI)) or any organ or space infections (OS-SSI), is a serious national health problem, affecting approximately 500,000 people in the United States each year [1]. It is the second most frequent nosocomial infection, which accounts for 40% of all the healthcare-related infections in patients undergoing surgery [2]. SSI is correlated with staying at a hospital for a long time, high readmission rates, poor quality of life, and huge healthcare costs [3–5]. It is one of the important indices of medical safety evaluation.

In general, the patients undergoing surgery, particularly those who undergo surgery for colorectal diseases, are more likely to develop SSI [6, 7]. Although their etiology is multifactorial, the majority of SSIs are preventable [8]. Multiple factors can affect the development of SSI, including patient-related factors (such as obesity, diabetes mellitus, age, gender, and smoking) and treatment-related factors (such as laparoscopic procedure, prophylactic antibiotics, and stoma creation) [5, 8-10]. Unsatisfactorily, few risk factors are generally accepted and some findings on these factors in medical literature are often contradictory. Accordingly, many perioperative interventions are supported by very limited literature evidence. More importantly, many scholars have realized that the risk factors are different for the different types of SSI. The understanding of these risk factors might better prevent and treat SSI. Besides, SSI reduces the benefits of surgical treatment. Therefore, systematically assessing the common factors of the different types of SSI is a priority. In our previous report [10], some risk factors of SSI in the patients with colorectal cancer (CRC) were presented and the associated concomitant changes and explanatory reasons were also provided. However, some patients, undergoing colorectal surgery (CRS), were excluded, which included patients with benign lesions, diverticular disease, ulcerative colitis, Crohn's disease, volvulus, bowel obstruction, or other conditions. Therefore, this meta-analysis was conducted to review the potential

PLOS ONE | https://doi.org/10.1371/journal.pone.0259107 October 28, 2021

risk factors of SSIs, incisional SSI (I-SSI), and OS-SSI in the patients undergoing surgery, thereby further assessing the evidence grading and aiming to offer help to clinical treatments.

# Method

The study protocol was registered with the PROSPERO database (registration ID: CRD42020178270), which is an international perspective registry for systematic reviews.

#### Search strategy

Peer-reviewed literature in the PubMed, Cochrane Library and EMBASE databases were thoroughly and systematically searched using a similar strategy for each database from inception to May 2020 (cut-off date 1<sup>st</sup> May 2020). The exact search strategy included searching the following mesh terms in each database: (colorectal surgery, colectom<sup>\*</sup>, or proctectom<sup>\*</sup>); ([colon, sigmoid, rectum, large bowel, bowel, colonic, rectal, or colorectal] and [excision, resection, surgical, surgically, surgery, or procedure]); (surgical site infection<sup>\*</sup>, surgical wound infection<sup>\*</sup>, or postoperative wound infection); and (risk factor<sup>\*</sup>). The reference list of all the included studies was screened to extend the search. The detailed search strategy for each database is provided in the <u>S1 Table</u>.

#### Inclusion and exclusion criteria

The study inclusion criteria were defined by PICOS (population, interventions, comparator, outcomes, and study design) categories [11].

Studies that reported the following were included in this study: (a) Patients who underwent CRS; (b) Related risk factor interventions were reported; (c) The main outcome was the incidence of SSI; (d) Studies providing effect estimates (relative risks (RRs) or odds ratios (ORs)) with corresponding 95% confidence interval (CIs). (e) Case-control or cohort studies.

Review articles, conference abstracts, unpublished gray literature, study protocols, letters, animal experiments, and studies with insufficient and overlapping data (when using the same data source and overlapping search period, there was overlapping data, which was avoided by only selecting the most recent or high-quality articles) were excluded from the current study.

#### Data extraction

Two researchers (ZhaoHui Xu and Hui Qu) independently extracted the details of the included studies, including the name of the first author, publication year, year of the study, study design, study size, country, risk factors, surgical types, definition and classification of SSI, the number of patients and average follow-up time, and quality score of Newcastle– Ottawa Quality Assessment Scale (NOS). The multivariate RRs/ORs with 95% CIs were preferred rather than univariate results. Any disagreement, if found, was resolved based on the assessment of a senior investigator (Xin Chen).

#### Quality assessment

Quality was assessed by scoring the 3 evaluating indicators of NOS, which included the selection of study groups, inter-comparability of groups, and outcomes, with a maximum score of 9 stars [12]. The score of each included study was also evaluated. The studies having scores of  $\geq 6$  stars were considered to be of relatively higher quality; the final results are provided in the S2 Table.

This study was conducted in strict conformity with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [13] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14].

#### Assessment of the strength of evidence

The strength of evidence was evaluated using the total sample size >1000, Egger's *P*-value >0.1, and intergroup inconsistency ( $I^2$ ) <50%. The Class I (high-quality) evidence referred to when the three conditions were met simultaneously. Class II (moderate-quality) and Class III (moderate-quality) evidence were defined as satisfying the two and one conditions of the three conditions, respectively. Class IV (low-quality) evidence was defined as satisfying none of these conditions [15].

#### Statistical analyses

All the statistical analyses were performed using Review Manager (RevMan) software (version 5.3; The Nordic Cochrane Centre, Copenhagen, Denmark) and Stata software (version 15.1). The pooled RRs and 95% Cis from the studies were analyzed using the DerSimonian–Laird random-effects model [16]. A two-tail *P* value of 0.05 or below was considered statistically significant.

The inter-group heterogeneity was examined using Cochran's Q ( $\chi 2$ ) test and quantified by the I<sup>2</sup> statistic. The heterogeneities were categorized into three groups based on the I<sup>2</sup> value (low group <50%, moderate group 50–74%, and high group  $\geq$ 75%) [17]. Sensitivity analyses were performed to recognize the potential sources of heterogeneities by changing the effect model or removing one study at a time. Publication bias was evaluated using funnel plots, Begg's test [18], and Egger's test [19]. The funnel plot asymmetry was further corrected using the trim and fill method.

#### Results

#### Study characteristics

In the initial search, a total of 2660 potentially eligible studies were identified, of which 643 duplicated studies were excluded. A total of 1836 articles, including review studies, case reports, letters, animal studies, or unrelated studies, were excluded, leaving only 181 studies reviewed by the two independent investigators for full text. Thus, 31 studies were finally included. Nine of these studies were prospective cohort studies, while the remaining were retrospective cohort studies. The baseline characteristics of the included articles are presented in Table 1. The flow diagram for the study procedure is presented in Fig 1.

# **Risk factors of SSI**

A total of 39 risk factors were found from the selected 31 articles. Among them, 25 factors could not be quantitatively analyzed in the study without adequate data sources and were excluded. Finally, 14 risk factors, reported in more than 2 studies, were included in this study, on which the meta-analysis was performed.

#### **Unmodifiable factors**

**Male sex.** Eight studies [5, 9, 20-25] were identified in the present study, showing that the male sex was a statistically significant risk factor for SSI (RR = 1.30, 95% CI: 1.14–1.49,  $I^2 = 59\%$ ) (Fig 2A).

Study	nation	Data sources	Recruited period	Procedures	No.of patients	Study type	Risk factors
Kwaan2013 <sup>38</sup>	USA	the University of Minnesota	2008-2009	CRS	143	retrospective cohort study	1.2.29.30
Kwaan2015 <sup>35</sup>	USA	the ACS NSQIP database	2005-2012	CRS	112,282	retrospective cohort study	1.3.4.5.6.7.8.24.25
Bot2013 <sup>21</sup>	France	the Lille University Hospital and a private hospital	June 2004-Dec 2011	CRC	740	retrospective cohort study	4.7.8.9.10.11.16.19.20.31
Bert2017 <sup>39</sup>	Italy	the SNICh database	Jan 2012-Dec 2012	CS	1322	retrospective cohort study	1.7.10.12
Poeran2016 <sup>25</sup>	USA	the Premier Perspective database	Jan 2006-Dec 2013	CS	90725	retrospective cohort study	3.9.12.13.21.22.23.25.26.27
Guzman-Pruneda 2018 <sup>34</sup>	USA	the Ohio State University Wexner Medical Center	Jan 2010-Dec 2016	CRS	469	retrospective cohort study	2.3.4.7.11.21
Ho2011 <sup>40</sup>	USA	The NewYork-Presbyterian Hospital /Weill Cornell Medical Center	June 2001-July 2008	CRS	650	retrospective cohort study	1.6.7.10.11
Nakamura2008 <sup>41</sup>	Japan	the Kitasato University Hospital	Jan 2004-Dec 2005	CRC	144	retrospective cohort study	7
Hennessey2015 <sup>42</sup>	Ireland	3 institutions	2007-2009	CRS	386	retrospective cohort study	7.12.14.25
Uchino2013 <sup>43</sup>	Japan	the Hyogo College of Medicine	Jan 2008-Dec 2011	CD	405	prospective cohort study	11.25
Tang 2001 <sup>32</sup>	China	the Chang Gung Memorial Hospital	Feb 1995-Dec 1998	CRS	2809	prospective cohort study	11.13.15.16
Biondo2012 <sup>28</sup>	Spain	the Spanish Rectal Cancer Project	May 2006-May 2009	RC	2131	retrospective cohort study	7.10.13.15.18.25
Bislenghi2019 <sup>20</sup>	Belgium	the University Hospitals Leuven	Oct 2016-Jan 2017	CRS	287	prospective cohort study	5.9.14.21.37
Itatsu2013 <sup>44</sup>	Japan	19 affiliated hospitals	Nov 2009-Feb 2011	CRC	1980	prospective cohort study	1.11.28.32.33
Hibbert2015 <sup>23</sup>	Saudi Arab	the King Faisal Specialist Hospital & Research Centre	not involved	CRS	296	prospective cohort study	9
Hubner2011 <sup>29</sup>	Switzerland	9 secondary and tertiary care public Swiss hospitals,	Mar 1998-Dec 2008	CS	2393	prospective cohort study	7.12.13.14
Wick2011 <sup>27</sup>	USA	8 different BCBS insurance plans	Jan 2000-Dec 2008	CRS	7020	retrospective cohort study	7.9.13
Blumetti2007 <sup>45</sup>	USA	a single tertiary care institution	Jan 2002-Dec 2005	CRS	428	retrospective cohort study	11.12
Tserenpuntsag2014 <sup>26</sup>	USA	the 174 NYS hospitals	2009–2010	CS	2656	retrospective cohort study	9.10.13.15.27.38
Imai2008 <sup>30</sup>	Japan	the Keio University Hospital	Aug 1997-Dec 2005	CC	801	retrospective cohort study	4.7.10.13.
Colas-Ruiz 2018 <sup>46</sup>	Spain	the HUFA in Madrid	Jan 2013-Dec 2016	RS	154	prospective cohort study	15.16.21
Park 2015 <sup>36</sup>	Korea	the Kyung Hee University Hospital, Gangdong	Jan 2010-May 2014	CRC	327	retrospective cohort study	4.5.7.10.14.15.19.35
Silvestri2017 <sup>37</sup>	Italy	the University Hospital of Trieste	June 2010-July 2014	CRS	687	retrospective cohort study	1.4.12
Cima2017 <sup>22</sup>	USA	the Mayo Clinic Hospital	Apr 2006-June 2014	CRS	2376	retrospective cohort study	3.4.7.9.10.17.22
Watanabe2015 <sup>47</sup>	Japan	the Nippon Medical School Musashikosugi Hospital	July 2005-May 2010	CRS	538	retrospective cohort study	1.7.10
Mason2016 <sup>31</sup>	UK	the Colchester University Hospital	Sep 2012-July 2014	CRS	246	retrospective cohort study	3.4.13.18.21.39
Mik2016 <sup>24</sup>	Poland	the Medical University of Lodz and the Centre for Treatment of Bowel Diseases Hospital in Brzeziny	Jan 2008-Dec 2015	CRC	2240	retrospective cohort study	6.9.12.14.25

#### Table 1. General characteristics of the included studies in the meta-analysis.

(Continued)

Study	nation	Data sources	Recruited period	Procedures	No.of patients	Study type	Risk factors
Olmez2019 <sup>48</sup>	Turkey	the Kosuyolu Resarch and Education Hospital	Jan 2013-July 2019	CRC	209	retrospective cohort study	7.14
Uchino2009 <sup>49</sup>	Japan	the Hyogo College of Medicine	Mar 2006-Dec 2007	CRS	562	prospective cohort study	10.11.22.25.36
Ghuman2015 <sup>33</sup>	Canada	The St. Paul's Hospital	Dec 2012-July 2014	CS	205	retrospective cohort study	3.4
Poon 2009 <sup>50</sup>	China	the Queen Mary Hospital,	Jan2002-Dec 2006	CRC	1011	prospective cohort study	7.15.34

*Remark:* 1. Wound classification $\geq$ 3; 2.Oral antibiotics; 3.Cigarette smoking; 4.Diabetes mellitus; 5.Pulmonary comorbidities; 6.Radiation therapy; 7.Open vs minimally invasive surgery (MIS); 8.Advanced tumors; 9.Obesity; 10.ASA grade  $\geq$ 3; 11.Ostomy creation; 12.Emergent surgery; 13.Male gender; 14.Operation time ( $\geq$ 180 min); 15. Blood transfusion; 16.Intra-abdominal drain; 17.Steroid use; 18.Converted to open procedure; 19.Hemoglobin level<10g/dL; 20.Blood loss $\geq$ 500 mL; 21.Neoplasm; 22. Inflammatory Bowel Disease; 23.Diverticular Disease; 24.Cardiac comorbidity; 25.Resection procedure (Abdominoperineal resection, pelvic exenteration, extended resection, etc); 26.Hospital location; 27.Hospital Teaching Status; 28.Chronic liver disease; 29.Abdominal wall thickness (AW2); 30.History of soft tissue infection; 31. Malnutrition; 32. Previous laparotomy; 33.Wound length; 34. Anastomotic leakage; 35. Estimated blood loss ( $\geq$ 100 mL); 36. Preoperative hospital stay>6 days; 37. Preoperative stoma; 38.Bed size>500 vs  $\leq$ 500; 39. Use of CO2 conditioner.

Abbreviations: BCBS: Blue Cross and Blue Shield; CC: colon cancer; CD: Crohn's disease; CRC: colorectal cancer; CRS: colorectal surgery; CS: colon surgery; HUFA: Hospital Universitario Fundación Alcorcón; NYS: New York State; RC: rectal cancer; RS: rectal surgery; SNICh: the National System of Surveillance of Surgical Site Infections.

https://doi.org/10.1371/journal.pone.0259107.t001




Fig 1. Flow chart of literature search and data extraction.

https://doi.org/10.1371/journal.pone.0259107.g001

Α.	Study or Subgroup	log[Risk Ratio]	SE		Risk Ratio IV, Random, 95% Cl	Risk Ratio IV, Random, 95% Cl	
	Biondo 2012 Hubner 2011	0.32570014 0.41871034	0.1315494	13.2% 14.7%	1.39 (1.07, 1.79) 1.52 (1.21, 1.91)	-	
	Imai 2008 Mason 2016	0.2723146 1.22964055	0.21415492 0.56848906	7.4%	1.31 [0.86, 2.00] 3.42 [1.12, 10.42]		
	Poeran 2016	0.22314355	0.06692966	20.2%	1.25 [1.10, 1.43]	-	
	Tang 2001 Tserenpuntsag 2014	0.40546511 0.29266961	0.20113708 0.10032394	8.1% 16.4%	1.50 (1.01, 2.22) 1.34 (1.10, 1.63)	-	
	Wick 2011	-0.02020271	0.08013146	18.7%	0.98 [0.84, 1.15]	+	
	Total (95% CI)			100.0%	1.30 [1.14, 1.49]	•	
	Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z =	02; Chi <sup>a</sup> = 17.16, = 3.79 (P = 0.000	df= 7 (P = 0.0 2)	2); I <sup>2</sup> = 59	%	0.05 0.2 1 5 Favours (experimental) Favours (control)	20
в	Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% CI	
	Bislenghi 2019	0.82855182	0.59691531	0.5%	2.29 [0.71, 7.38] 1.89 [1.12, 3.20]		
	Bot 2013 Cima 2017	0.63657683 0.51879379	0.2685003	2.5% 5.8%	1.68 [1.20, 2.35]		
	Hibbert 2015 Mik 2016	1.54968791	0.38879542 0.02446942	1.2%	4.71 [2.20, 10.09]		-
	Poeran 2016	0.44468582	0.0974323	14.5%	1.56 (1.29. 1.89)		
	Tserenpuntsag 2014 Wick 2011	0.39204209 0.46373402	0.10131794 0.09425294	13.7% 15.2%	1.48 [1.21, 1.81] 1.59 [1.32, 1.91]	-	
	Total (95% CI)			100.0%	1.60 [1.47, 1.74]	•	
	Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	00; Chi <sup>a</sup> = 9.28, d = 10.86 (P < 0.00	if = 7 (P = 0.23 1001)	); I² = 259	6	0.05 0.2 1 5 Favours [experimental] Favours [control]	20
_					Risk Ratio	Risk Ratio	
С	Study or Subgroup Bol 2013	log[Risk Ratio 0.32930375	1 SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
	Cima 2017	0.76080583	3 0.23637952	14.7%	1.39 [0.79, 2.44] 2.14 [1.35, 3.40]		
	Ghuman 2015 Guzman-Pruneda 2018	1.05431203			2.87 [1.30, 6.34] 2.06 [0.84, 5.03]		-
	Imai 2008	0.23031776	6 0.36549973	9.6%	1.26 [0.62, 2.58]		
	Kwaan 2015 Mason 2016	0.12221763	0.02951133 0.97418638		1.13 [1.07, 1.20] 1.36 [0.20, 9.18]		
	Park 2015 Silvestri 2017	0.7533011	0.35833183	9.8%	2.12 [1.05, 4.29]		
		0.01010000	+ 0.1030038/				
	Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.0	9; Chi <sup>2</sup> = 20.02. d	df= 8 (P = 0.01	100.0% ); l <sup>2</sup> = 60%	1.65 [1.24, 2.20]		10
	Test for overall effect Z=	3.42 (P = 0.0006	6)			0.1 0.2 0.5 1 2 5 Favours [experimental] Favours [control]	10
D	Church and Continues of	antDials D. d.		14/01-1-1	Risk Ratio	Risk Ratio	
•	Bislenghi 2019	0g[Risk Ratio] 1.14740245	0.54593525	33.1%	IV, Random, 95% CI 3.15 [1.08, 9.18]	IV, Random, 95% Cl	
	Kwaan 2015 Park 2015	0.19885086	0.0312761 0.97377709	46.8%	3.15 [1.08, 9.18] 1.22 [1.15, 1.30] 11.43 [1.69, 77.04]	· · · · ·	_
	Total (95% CI)			100.0%	2.62 [0.84, 8.13]	-	
	Heterogeneity: Tau <sup>2</sup> = 0	.71; Chi² = 8.27,	df = 2 (P = 0.0		%	0.01 0.1 1 10	100
	Test for overall effect: Z	= 1.66 (P = 0.10)	)			Favours (experimental) Favours (control)	
_					Risk Ratio	Risk Ratio	
E	Study or Subgroup Bert 2017	0.45107562	0.10141902	Weight 11.2%	IV, Random, 95% Cl 1.57 [1.10, 2.24]	IV, Random, 95% Cl	
	Biondo 2012	0.14496577	0.1229674	24.4%	1.16 [0.91, 1.47]		
	Bot 2013 Cima 2017	0.19062036 0.41210965	0.28147012 0.17682326	4.7%	1.21 [0.70, 2.10] 1.51 [1.07, 2.14]		
	Ho 2011	0.13976194	0.26743634	5.2%	1.15 [0.68, 1.94]		
	Imai 2008 Park 2015	-0.05657035 0.3357577	0.39730019 0.4800752	2.3% 1.6%	0.95 (0.43, 2.06) 1.40 (0.55, 3.58)		
	Tserenpuntsag 2014 Uchino 2009	0.28517894 0.71294981	0.1065651 0.33451897	32.5% 3.3%	1.33 [1.08, 1.64] 2.04 [1.06, 3.93]		
	Watanabe 2015	0.7975072	0.35014392	3.0%	2.22 [1.12, 4.41]		
	Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.	00; Chi <sup>2</sup> = 7.56, c	if = 9 (P = 0.58	100.0% ); I <sup>2</sup> = 0%	1.34 [1.19, 1.51]	◆ 0.05 0.2 1 5	20
	Test for overall effect Z	= 4.86 (P < 0.000	101)			Favours [experimental] Favours [control]	20
F	Study or Subgroup	og[Risk Ratio]	SE	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	
	Bert 2017	-0.03045921	0.22130116	8.0%	0.97 [0.63, 1.50]		
	Blumetti 2007 Hennessey 2015		0.33144974 0.40234108	3.9% 2.7%	2.30 [1.20, 4.40] 1.38 [0.63, 3.04]		
	Hubner 2011 Mik 2016	0.44468582 0.29266961	0.15946268	13.2% 43.8%	1.56 [1.14, 2.13] 1.34 [1.30, 1.39]		
	Poeran 2016	0.19062036	0.09224827	24.9%	1.21 [1.01, 1.45]	-	
	Silvestri 2017	0.91629073	0.35209888	3.5%	2.50 [1.25, 4.98]		
	Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0	.01; Chi <sup>2</sup> = 10.06	i, df = 6 (P = 0.	100.0% 12); I <sup>2</sup> = 4	1.36 [1.19, 1.55] 0%	0.1 0.2 0.5 1 2 5	10
	Test for overall effect: Z	= 4.44 (P < 0.00	001)			Favours [experimental] Favours [control]	
G	Study or Subgroup	log[Risk Ratio	I SE	Weight	Risk Ratio IV, Random, 95% Cl	Risk Ratio IV, Random, 95% Cl	
	Bislenghi 2019 Colas-Ruiz 2018	-0.38566248 0.70309751	8 0.04513538	29.5%	0.68 [0.62, 0.74] 2.02 [0.18, 22.46]		
	Guzman-Pruneda 2018	0.80200158	8 0.42195885	22.0%	2.23 [0.98, 5.10]		
	Mason 2016 Poeran 2016	-0.63487827 0.88789126			0.53 [0.16, 1.72] 2.43 [1.20, 4.93]		
	Total (95% CI)			100.0%	1.24 [0.58, 2.66]	•	
	Heterogeneity: Tau <sup>2</sup> = 0.5 Test for overall effect Z =	i1; Chi² = 20.79, 0 0.55 (P = 0.58)	df = 4 (P = 0.00			0.01 0.1 1 10 Favours (experimental) Favours (control)	100
						rours (experimental) in anoune (control)	
н	dudy or Subgroup	og[Risk Ratio]	SF		Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% Cl	
	Dima 2017 Poeran 2016	0.43469624	0.24259599	37.4%	1.64 [1.02, 2.64] 4.08 [2.06, 8.10]		
	Jehino 2009	0.43489224		28.4%	4.08 [2.06, 8.10] 1.62 [C.94, 2.80]		
	fotal (95% CI)			100.0%	2.12 [1.24, 3.61]	•	
	-leterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect Z	.14; Chi# = 5.38, = 2.75 (P = 0.00	df=2 (P=0.0 6)	7); F= 63	%	0.01 0.1 1 10 Favours (control)	100
					Diele D-41-	Piete Deale	
I	audy or Subgroup	on[Risk Ratio]	SE	Weight 18.7%	Risk Ratio IV, Random, 95% CI	Risk Ratio	
	3ert 2017 10 2011	2.21811594	0.19738551 0.66040254	9.7%	2.02 [1.37, 2.97] 9.19 [2.52, 33.53]		_
	atsu 2013 (waan 2013	1.17248214	0.38331998	14.9%	3.23 [1.52, 6.85] 2.80 [0.74, 10.60]		
	(waan 2015	0.18551444	0.03030192	20.5%	1.18 [1.11, 1.25]	•	
	3ilvestri 2017	0.57097955	0.56051647	11.4%	1.77 [0.59, 5.31]		
	Vatanabe 2015	1.66581825	0.35870776	15.4%	5.29 [2.62, 10.69]		
	Vatanabe 2015	1.66581825	0.35870776			-	
	'otal (95% Cl) leterogeneity: Tau²= 0	.39; Chi² = 42.19	8, df= 6 (P < 0.	100.0%	2.65 [1.52, 4.61]		50
	otal (95% CI)	.39; Chi² = 42.19	8, df= 6 (P < 0.	100.0%	2.65 [1.52, 4.61]	0.02 0.1 1 10 Favours (experimental) Favours (control)	50

Fig 2. The forest plots showed that the correlations between the risk of SSIs with (A) male sex, (B) obesity, (C) diabetes mellitus, (D) respiratory disease, (E) ASA classification, (F) emergent status, (G) neoplasm, (H) inflammatory bowel disease, (I) wound classification>2.

https://doi.org/10.1371/journal.pone.0259107.g002

**Obesity.** The World Health Organization (WHO) definition for obesity was used, which defines obesity as body mass index (BMI) greater than 30 kg/m<sup>2</sup> [26]. A meta-analysis of the eight studies [21, 23, 24, 27–31], which reported obesity, showed that the obese patients were positively correlated with the rate of SSI (RR = 1.60, 95% CI: 1.47–1.74,  $I^2 = 25\%$ ) (Fig 2B).

**Diabetes mellitus.** Nine studies [20, 25, 27, 30, 32–36], including 118,133 patients, showed that there was a positive linear proportional correlation between the diabetes mellitus and rate of SSIs in the patients undergoing CRS (RR = 1.65, 95% CI: 1.24–2.20,  $I^2 = 60\%$ ) (Fig 2C).

**Respiratory comorbidity.** Three studies [31, 33, 34] reported the connection between respiratory comorbidity and SSI. The synthetic results of these studies showed that there was a significant correlation between them in the patients undergoing CRS (RR = 2.62, 95% CI: 0.84–8.13,  $I^2 = 76\%$ ) (Fig 2D).

American Society of Anesthesiologists (ASA) classification. Among ten studies [20, 22, 23, 27, 30, 34, 37–40], the combined results of meta-analysis revealed that the ASA score of higher than or equal to 3 showed an increased risk of developing SSI (RR = 1.34, 95% CI: 1.19–1.51,  $I^2 = 0\%$ ) (Fig 2E).

**Emergent surgery.** The results of seven studies [5, 24, 29, 35, 40-42] showed that the emergent status could increase the risk of SSI by 36% (RR = 1.36, 95% CI: 1.19–1.55, I<sup>2</sup> = 40%) (Fig 2F).

**Neoplasm.** The meta-analysis of five studies [24, 25, 31, 36, 43] found that there was not a significant correlation between neoplasm and SSI (RR = 1.24, 95% CI: 0.58–2.26,  $I^2 = 81\%$ ) (Fig 2G).

**Inflammatory Bowel Disease(IBD).** The meta-analysis of three studies [24, 30, 37], reporting IBD, indicated that IBD could increase the SSI rate (RR = 2.12, 95% CI: 1.24–3.61,  $I^2 = 63\%$ ) (Fig 2H).

**Wound classification**>2. The association between wound classification and SSI was investigated in seven studies [33, 35, 38–40, 44, 45]. The pooled results indicated that the wound classification >2 might increase the occurrence of SSI (RR = 2.65, 95% CI: 1.52–4.61,  $I^2 = 86\%$ ) (Fig 21).

#### Modifiable factors

**Operative time** ( $\geq$ 180 min). Six studies [5, 29, 31, 34, 42, 46] focused on the effects of surgery duration. There was an 88% increase in the risk of SSI for the surgeries having the duration of longer than 180 min (RR = 1.88, 95% CI: 1.49–2.36, I<sup>2</sup> = 58%) (Fig 3A).


**Cigarette smoking.** The pooled data from six studies [24, 25, 30, 32, 33, 36] showed that the smoking patients had a 1.22-fold increased risk of developing SSI as compared to the non-smoking patients (RR = 1.38, 95% CI: 1.14–1.67,  $I^2 = 64\%$ ) (Fig 3B).

**Open surgery.** A meta-analysis of sixteen studies [5, 20-22, 27, 30, 33, 34, 36, 38-40, 42, 46-48] showed that the patients who accepted laparotomy had a 1.81-fold increased risk of developing SSI as compared to the patients with laparoscopic surgery (RR = 1.81, 95% CI: 1.57-2.10, I<sup>2</sup> = 69%) (Fig 3C).

**Stoma formation.** The pooled analysis of eight studies [9, 27, 36–38, 41, 45, 49] suggested that the risk of SSI in the patients having in-hospital stoma formation was 1.89 times higher than those who did not have one (RR = 1.89, 95% CI: 1.28–2.78,  $I^2 = 69\%$ ) (Fig 3D).

**Blood transfusion**. The pooled results of five studies [22, 23, 34, 43, 48] indicated that the perioperative blood transfusion increased the risk of developing SSIs by 103% (RR = 2.03, 95% CI:1.34–3.06,  $I^2 = 74\%$ ) (Fig 3E).

1	Study or Subgroup	log[Risk Ratio]	SE	Weight N	Risk Ratio V, Random, 95% Cl	Risk Ratio IV, Random, 95% Cl	
	Bislenghi 2019	1.07500242 0		5.9%	2.93 [1.24, 6.93]	· · · · ·	
	Hennessey 2015		0.3241501	9.7%	4.34 [2.30, 8.20]		
	Hubner 2011	0.42526774 0		28.3%	1.53 [1.22, 1.92]	-	
	Mik 2016	0.49469624 0		39.3%	1.64 [1.59, 1.70]		
	Olmez 2019	0.48242615 0		8.4%	1.62 [0.81, 3.24]	+ <b>-</b>	
	Park 2015	0.81181871 0		8.3%	2.25 [1.12, 4.54]	<b>.</b>	
	Total (95% CI)			100.0%	1.88 [1.49, 2.36]		
	Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z			J4); I*= 58	196	0.01 0.1 1 10	10
						Favours [experimental] Favours [control]	
	Study or Subgroup	log[Risk Ratio]	SE	Weight	Risk Ratio IV, Random, 95% Cl	Risk Ratio IV, Random, 95% Cl	
	Cima 2017		0.20512864	14.7%	1.47 [0.98, 2.20]		
	Ghuman 2015	1.4632554	0.47494835	3.9%	4.32 [1.70, 10.96]		_
	Guzman-Pruneda 2018	0.89199804	0.3077934	8.2%	2.44 [1.33, 4.46]	· · · · · ·	
	Kwaan 2015	0.21511138			1.24 [1.18, 1.31]	-	
	Mason 2016		0.73910515		1.70 [0.40, 7.24]		
	Poeran 2016		0.07790348		1.14 [0.98, 1.33]	-	
	Total (95% CI)			100.0%	1.38 [1.14, 1.67]	•	
	Heterogeneity: Tau <sup>2</sup> = 0.	.02; Chi <sup>2</sup> = 13.77, d <sup>.</sup>	f = 5 (P = 0.02				
	Test for overall effect Z					0.05 0.2 1 Ś Favours [experimental] Favours [control]	2
					Risk Ratio	Risk Ratio	
	Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
	Bert 2017		0.26600302		1.55 [0.92, 2.61]	+	
	Biondo 2012		0.15899081	9.0%	1.07 [0.78, 1.46]	+	
	Bot 2013		0.27076096		5.11 [3.01, 8.69]		
	Cima 2017	0.3852624	0.17804677	8.1%	1.47 [1.04, 2.08]		
	Guzman-Pruneda 2018	1.96571278	0.5484347	1.6%	7.14 [2.44, 20.92]		
	Hennessey 2015	0.10436002	0.33064879	3.8%	1.11 [0.58, 2.12]		
	Ho 2011	0.14842	0.3437277	3.6%	1.16 [0.59, 2.28]		
	Hubner 2011	0.94000726	0.17186967	8.4%	2.56 [1.83, 3.59]		
	lmai 2008		0.22353246		1.66 [1.07, 2.57]		
	Kwaan 2015	0.5988365	0.02365036	15.1%	1.82 [1.74, 1.91]		
	Nakamura 2008	1.20357272	0.5178345		3.33 [1.21, 9.19]		
	Olmez 2019	1.3428648	0.56585912	1.5%	3.83 [1.26, 11.61]		
	Park 2015	0.52472853	0.05959562	14.0%	1.69 [1.50, 1.90]	•	
	Poon 2009	0.86750057	0.4105709	2.7%	2.38 [1.06, 5.32]		
	Watanabe 2015		0.40184032		2.21 [1.01, 4.86]		
	Wick 2011	0.45107562	0.11604336	11.1%	1.57 [1.25, 1.97]		
	Total (95% CI)			100.0%	1.81 [1.57, 2.10]		
	Heterogeneity: Tau <sup>2</sup> = 0.1 Test for overall effect: Z =			001); I² = 6	9%	0.01 0.1 1 10 Favours [experimental] Favours [control]	10
					Risk Ratio	Risk Ratio	
)	Study or Subaroup	log[Risk Ratio]	1 SE	- Weight		IV. Random, 95% Cl	
)	Study or Subgroup Blumetti 2007	log[Risk Ratio] 0.64185389			IV, Random, 95% Cl		
	Study or Subgroup Blumetti 2007 Bot 2013	0.64185389	1 SE 3 0.24211239 3 0.40070632	3 14.6%	IV, Random, 95% Cl 1.90 [1.18, 3.05]		
	Blumetti 2007	0.64185389 0.2390169	0.24211239	9 14.6% 2 10.6%	IV, Random, 95% Cl 1.90 [1.18, 3.05] 1.27 [0.58, 2.79]		
)	Blumetti 2007 Bot 2013	0.64185389 0.2390169 8 0.03922071	9 0.24211239 9 0.40070632	9 14.6% 2 10.6% 9 9.3%	IV, Random, 95% Cl 1.90 [1.18, 3.05]	 	
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011	0.64185389 0.2390169 0.03922071 -0.27443685	<ul> <li>0.24211239</li> <li>0.40070633</li> <li>0.46010049</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0%	<b>IV, Random, 95% Cl</b> 1.90 [1.18, 3.05] 1.27 [0.58, 2.79] 1.04 [0.42, 2.56] 0.76 [0.42, 1.37]		
)	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018	0.64185389 0.2390169 0.03922071 -0.27443685 0.82855182	<ul> <li>0.24211239</li> <li>0.40070632</li> <li>0.46010049</li> <li>0.30161003</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9%	<b>IV, Random, 95% Cl</b> 1.90 [1.18, 3.05] 1.27 [0.58, 2.79] 1.04 [0.42, 2.56]		
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013	0.64185389 0.2390169 3 0.03922071 -0.27443685 0.82855182 0.74193734	<ul> <li>0.24211239</li> <li>0.40070633</li> <li>0.46010049</li> <li>0.30161003</li> <li>0.34364124</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9% 3 14.1%	V, Random, 95% Cl 1.90 (1.18, 3.05) 1.27 (0.58, 2.79) 1.04 (0.42, 2.56) 0.76 (0.42, 1.37) 2.29 (1.17, 4.49)		
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001	0.64185389 0.2390169 0.03922071 -0.27443685 0.82855182 0.74193734 1.22524494	<ul> <li>0.24211238</li> <li>0.40070633</li> <li>0.46010049</li> <li>0.30161003</li> <li>0.34364124</li> <li>0.25983918</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4%	V, Random, 95% Cl 1.90 [1.18, 3.05] 1.27 [0.58, 2.79] 1.04 [0.42, 2.56] 0.76 [0.42, 1.37] 2.29 [1.17, 4.49] 2.10 [1.26, 3.49]		
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI)	0.64185389 0.2390168 3 0.03922071 -0.27443685 0.82855182 0.74193734 1.22524494 1.37371558	<ul> <li>0.24211238</li> <li>0.40070632</li> <li>0.46010048</li> <li>0.30161002</li> <li>0.34364124</li> <li>0.25983916</li> <li>0.28492962</li> <li>0.29852758</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0%	V, Random, 95% CI 1.90 (1.18, 3.05) 1.27 (1.58, 2.79) 1.04 (0.42, 2.56) 0.76 (0.42, 1.27) 2.29 (1.17, 4.49) 2.10 (1.26, 3.49) 3.41 (1.95, 5.95) 3.95 (2.20, 7.09) 1.89 (1.28, 2.78)		
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itateu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0	0.64185389 0.2390188 0.03922071 -0.27443685 0.82855182 0.74193734 1.22524494 1.37371558	<ul> <li>0.2421123(</li> <li>0.40070632</li> <li>0.4601004(</li> <li>0.30161002</li> <li>0.34364124</li> <li>0.2590391(</li> <li>0.28492962</li> <li>0.2985275(</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0%	V, Random, 95% CI 1.90 (1.18, 3.05) 1.27 (1.58, 2.79) 1.04 (0.42, 2.56) 0.76 (0.42, 1.27) 2.29 (1.17, 4.49) 2.10 (1.26, 3.49) 3.41 (1.95, 5.95) 3.95 (2.20, 7.09) 1.89 (1.28, 2.78)		
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI)	0.64185389 0.2390188 0.03922071 -0.27443685 0.82855182 0.74193734 1.22524494 1.37371558	<ul> <li>0.2421123(</li> <li>0.40070632</li> <li>0.4601004(</li> <li>0.30161002</li> <li>0.34364124</li> <li>0.2590391(</li> <li>0.28492962</li> <li>0.2985275(</li> </ul>	9 14.6% 2 10.6% 9 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0%	V, Random, 95% CI 1.90 (1.18, 3.05) 1.27 (1.58, 2.79) 1.04 (0.42, 2.56) 0.76 (0.42, 1.27) 2.29 (1.17, 4.49) 2.10 (1.26, 3.49) 3.41 (1.95, 5.95) 3.95 (2.20, 7.09) 1.89 (1.28, 2.78)		11
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z	0.64185382 0.230116 0.03922071 -0.27443685 0.82855182 0.74139734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001)	<ul> <li>0.24211236</li> <li>0.46070632</li> <li>0.46010046</li> <li>0.30161002</li> <li>0.34364124</li> <li>0.25963916</li> <li>0.29852756</li> <li>df=7 (P=0.00000000000000000000000000000000000</li></ul>	3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0% 02); I <sup>*</sup> = 69	IV, Random, 95% CI           1,90 (1.18, 3.05)           1,27 (0.58, 2.79)           1,04 (0.42, 2.56)           0,76 (0.42, 1.37)           2,29 (1.17, 4.49)           2,10 (1.26, 3.49)           3,41 (1.95, 5.95)           3,95 (2.20, 7.09)           1,89 (1.28, 2.78)           %	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	11
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z	0.64185389 0.230116 0.03922071 -0.27443685 0.82855182 0.74193734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001)	<ul> <li>0.24211238</li> <li>0.40070633</li> <li>0.46070632</li> <li>0.30161003</li> <li>0.34364122</li> <li>0.25462916</li> <li>0.28492963</li> <li>0.29852756</li> <li>df=7 (P = 0.00</li> </ul>	3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0% 02); I² = 69 Weight	IV, Random, 95% Cl           1,90 (1.18, 3.05)           1,27 (D.58, 2.79)           1.04 (0.42, 2.56)           0.76 (0.42, 1.37)           2.29 (1.17, 4.49)           2.10 (1.26, 3.49)           3.41 (1.95, 5.95)           3.95 (2.20, 7.09)           1.89 [1.28, 2.78]           %	0.01 0.1 1 10 Favours [experimental] Favours [control]	10
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itateu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z <u>Study or Subgroup</u> Biondo 2012	0.64185389 0.2390188 0.03922071 -0.27443885 0.82856182 0.74193734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>Iog[Risk Ratio]</b> 0.89363604	<ul> <li>0.24211233</li> <li>0.40070633</li> <li>0.46070633</li> <li>0.30161003</li> <li>0.34364124</li> <li>0.25963916</li> <li>0.25963916</li> <li>0.29852753</li> <li>0.29852753</li> <li>df= 7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> </ul>	<ul> <li>14.6%</li> <li>10.6%</li> <li>9.3%</li> <li>13.0%</li> <li>4.11.9%</li> <li>14.1%</li> <li>13.4%</li> <li>13.1%</li> <li>100.0%</li> <li>12); I* = 69</li> <li>Weight</li> <li>29.9%</li> </ul>	<u>IV, Random, 95% CI</u> 1.90 (1.18, 3.05) 1.27 (10.58, 27.9) 1.04 (0.42, 2.56) 0.76 (0.42, 1.37) 2.29 (1.17, 4.49) 2.10 (1.26, 3.49) 3.41 (1.95, 5.95) 3.95 (2.20, 7.09) 1.89 (1.28, 2.78) % Risk Ratio <u>IV, Random, 95% CI</u> 2.44 (1.88, 3.17]	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	11
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z <u>Study of Subgroup</u> Biondo 2012 Colas-Ruiz 2018	0.64185382 0.2390168 0.03922071 -0.27443685 0.62855182 0.74139734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>log[Risk Ratio]</b> 0.88363604 0.45742485	<ul> <li>0.24211233</li> <li>0.40070633</li> <li>0.46010046</li> <li>0.30161002</li> <li>0.34364122</li> <li>0.24929633</li> <li>0.29852755</li> <li>df=7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> <li>0.60683016</li> </ul>	<ul> <li>3 14.6%</li> <li>2 10.6%</li> <li>3 13.0%</li> <li>4 11.9%</li> <li>3 14.1%</li> <li>2 13.4%</li> <li>5 13.1%</li> <li>100.0%</li> <li>12); I<sup>a</sup> = 69</li> <li>Weight</li> <li>29.9%</li> <li>8.9%</li> </ul>	IV, Random, 95% CI           1,90 [1.18, 3.05]           1,27 [0.58, 2.79]           1,04 [0.42, 2.56]           0.76 [0.42, 1.37]           2.29 [1.17, 4.49]           2.10 [1.26, 3.49]           3.41 [1.95, 9.59]           3.95 [2.20, 7.09]           1.89 [1.28, 2.78]           %           Risk Ratio           M. Andom, 95% CI           2.44 [1.88, 3.17]           1.58 [0.48, 5.19]	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	1(
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z <u>Study or Subgroup</u> Biondo 2012 Colas-Ruiz 2018 Park 2015	0.64185389 0.230116 0.03922071 -0.27443685 0.82855182 0.74139734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>log(Risk Ratio)</b> 0.89363604 0.45742485 1.13140211	<ul> <li>0.24211233</li> <li>0.40070633</li> <li>0.46070633</li> <li>0.30161003</li> <li>0.34364122</li> <li>0.25863914</li> <li>0.268492963</li> <li>0.29852753</li> <li>dr= 7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> <li>0.60683016</li> <li>0.35327618</li> </ul>	3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 5 13.1% 100.0% 12);  ² = 69 <u>Weight</u> 29.9% 8.9% 17.3%	IV, Random, 95% CI           1,90 (1.18, 3.05)           1,27 (0.58, 2.79)           1,04 (0.42, 2.56)           0,76 (0.42, 1.27)           2,29 (1.17, 4.49)           2,10 (1.26, 3.49)           3,41 (1.95, 5.95)           3,95 (2.20, 7.09)           1.89 (1.28, 2.78)           %           Risk Ratio           IV, Random, 95% CI           2,44 (1.88, 3.17)           3,50 (0.45, 5.19)           3,10 (1.55, 6.20)	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	11
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z <u>Study of Subgroup</u> Biondo 2012 Colas-Ruiz 2018	0.64185382 0.2390168 0.03922071 -0.27443685 0.62855182 0.74139734 1.22524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>log[Risk Ratio]</b> 0.88363604 0.45742485	<ul> <li>0.24211233</li> <li>0.40070633</li> <li>0.46070633</li> <li>0.30161003</li> <li>0.34364124</li> <li>0.25963916</li> <li>0.29852753</li> <li>0.29852753</li> <li>df= 7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> <li>0.6063016</li> <li>0.35327618</li> <li>0.45279397</li> </ul>	<ul> <li>3 14.6%</li> <li>2 10.6%</li> <li>3 13.0%</li> <li>4 11.9%</li> <li>3 14.1%</li> <li>2 13.4%</li> <li>5 13.1%</li> <li>100.0%</li> <li>12); I<sup>a</sup> = 69</li> <li>Weight</li> <li>29.9%</li> <li>8.9%</li> </ul>	IV. Random, 95% CI           1.90 [1.18, 3.05]           1.27 [0.58, 2.79]           1.04 [0.42, 2.56]           0.76 [0.42, 1.37]           2.29 [1.17, 4.49]           2.10 [1.26, 3.49]           3.41 [1.95, 5.95]           3.95 [2.20, 7.09]           1.89 [1.28, 2.78]           %           Risk Ratio           IV. Random, 95% CI           2.44 [1.88, 3.17]           1.58 [0.48, 5.19]           3.10 [1.55, 6.20]           2.43 [1.00, 5.90]	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	1
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect <i>Z</i> <u>Study or Subgroup</u> Biondo 2012 Colas-Ruiz 2018 Park 2015 Poon 2009 Tserenpuntsag 2014	0.64185389 0.230116 0.03922071 -0.27443685 0.82855182 0.74193734 1.32524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>log[Risk Ratio]</b> 0.89363604 0.45742485 1.13140211 0.88789126	<ul> <li>0.24211233</li> <li>0.40070633</li> <li>0.46070633</li> <li>0.30161003</li> <li>0.34364124</li> <li>0.25963916</li> <li>0.29852753</li> <li>0.29852753</li> <li>df= 7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> <li>0.6063016</li> <li>0.35327618</li> <li>0.45279397</li> </ul>	<ul> <li>3 14.6%</li> <li>2 10.6%</li> <li>3 9.3%</li> <li>3 13.0%</li> <li>4 11.9%</li> <li>3 14.1%</li> <li>2 13.4%</li> <li>5 13.1%</li> <li>100.0%</li> <li>12); I* = 69</li> <li>Weight</li> <li>29.9%</li> <li>8.9%</li> <li>17.3%</li> <li>13.2%</li> <li>30.7%</li> </ul>	IV, Random, 95% CI           1,90 (1.18, 3.05)           1,27 (0.58, 2.79)           1,04 (0.42, 2.56)           0,76 (0.42, 1.37)           2,29 (1.17, 4.49)           2,10 (1.26, 3.49)           3,41 (1.95, 5.95)           3,95 (2.20, 7.09)           1.89 (1.28, 2.78)           %           Risk Ratio           IV, Random, 95% CI           2,44 (1.88, 3.17)           1.58 (0.48, 5.19)           3,10 (1.55, 6.20)           2,43 (1.00, 5.90)           1,32 (1.05, 1.66)	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	10
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect Z <u>Study or Subgroup</u> Biondo 2012 Colas-Ruiz 2018 Park 2015 Poon 2009 Tserenpuntsag 2014 Total (95% CI)	0.64185389 0.2390168 0.03922071 -0.27443685 0.82855182 0.82855182 1.2524494 1.37371558 1.21; Chi <sup>2</sup> = 22.49, d = 3.21 (P = 0.001) <b>log[Risk Ratio]</b> 0.89363604 0.45742485 1.13140211 0.88769126 0.27763174	<ul> <li>0.24211233</li> <li>0.46070633</li> <li>0.36010045</li> <li>0.30161003</li> <li>0.34364124</li> <li>0.25963916</li> <li>0.29852753</li> <li>0.29852753</li> <li>df= 7 (P = 0.00</li> <li>SE</li> <li>0.13281883</li> <li>0.60683016</li> <li>0.35327618</li> <li>0.3527618</li> <li>0.45279397</li> <li>0.11684373</li> </ul>	3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 100.0% Weight 29.9% 8.9% 17.3% 30.7% 100.0%	IV, Random, 95% CI           1.90 [1.18, 3.05]           1.27 [0.58, 2.79]           1.04 [0.42, 2.56]           0.76 [0.42, 1.37]           2.29 [1.17, 4.49]           2.10 [1.26, 3.49]           3.41 [1.95, 5.95]           3.95 [2.20, 7.09]           1.89 [1.28, 2.78]           %           Risk Ratio           IV, Random, 95% CI           2.44 [1.88, 3.17]           1.58 [0.48, 5.19]           3.10 [1.55, 6.20]           2.43 [1.00, 5.90]           1.32 [1.05, 1.66]           2.03 [1.34, 3.06]	0.01 0.1 10 Favours [experimental] Favours [control] N. Random, 95% Cl	10
	Blumetti 2007 Bot 2013 Guzman-Pruneda 2018 Ho 2011 Itatsu 2013 Tang 2001 Uchino 2009 Uchino 2013 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect <i>Z</i> <u>Study or Subgroup</u> Biondo 2012 Colas-Ruiz 2018 Park 2015 Poon 2009 Tserenpuntsag 2014	0.64185382 0.230118 0.230118 0.2302071 0.27443885 0.2285182 0.7443885 0.2285492 0.7443885 1.21; Chi <sup>2</sup> = 22.49, d 3.21 (P = 0.001) 10g[Risk Ratio] 0.89363604 0.45742485 1.13140211 0.88769126 0.27763174 0.13; Chi <sup>2</sup> = 15.20,	<ul> <li>a) 0.24211233</li> <li>a) 0.46070633</li> <li>a) 0.46070633</li> <li>a) 0.46070643</li> <li>c) 0.30161002</li> <li>c) 0.34364122</li> <li>c) 0.28492962</li> <li>c) 0.28492962</li> <li>c) 0.28492962</li> <li>d) 2.8492962</li> <lid) 2.8492962<="" li=""> <lid) 2.8492962<="" li=""> <l< td=""><td>3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 100.0% Weight 29.9% 8.9% 17.3% 30.7% 100.0%</td><td>IV, Random, 95% CI           1.90 [1.18, 3.05]           1.27 [0.58, 2.79]           1.04 [0.42, 2.56]           0.76 [0.42, 1.37]           2.29 [1.17, 4.49]           2.10 [1.26, 3.49]           3.41 [1.95, 5.95]           3.95 [2.20, 7.09]           1.89 [1.28, 2.78]           %           Risk Ratio           IV, Random, 95% CI           2.44 [1.88, 3.17]           1.58 [0.48, 5.19]           3.10 [1.55, 6.20]           2.43 [1.00, 5.90]           1.32 [1.05, 1.66]           2.03 [1.34, 3.06]</td><td>0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio</td><td>10</td></l<></lid)></lid)></ul>	3 14.6% 2 10.6% 3 9.3% 3 13.0% 4 11.9% 3 14.1% 2 13.4% 100.0% Weight 29.9% 8.9% 17.3% 30.7% 100.0%	IV, Random, 95% CI           1.90 [1.18, 3.05]           1.27 [0.58, 2.79]           1.04 [0.42, 2.56]           0.76 [0.42, 1.37]           2.29 [1.17, 4.49]           2.10 [1.26, 3.49]           3.41 [1.95, 5.95]           3.95 [2.20, 7.09]           1.89 [1.28, 2.78]           %           Risk Ratio           IV, Random, 95% CI           2.44 [1.88, 3.17]           1.58 [0.48, 5.19]           3.10 [1.55, 6.20]           2.43 [1.00, 5.90]           1.32 [1.05, 1.66]           2.03 [1.34, 3.06]	0.01 0.1 10 Favours [experimental] Favours [control] Risk Ratio	10



https://doi.org/10.1371/journal.pone.0259107.g003

Significant factors	No. of studies	No. of patients	I2(%)	PEgger'S	P <sub>Begg-Mazumdar'S</sub>	RR	Evidence grading
SSIs							
Male sex	8	109727	59	0.106	0.174	1.30(1.14-1.49)	Class II (moderate-quality)
Obesity	8	106,340	25	0.161	0.063	1.60(1.47-1.74)	Class I (high-quality)
Diabetes mellitus	9	118,133	60	0.006	0.971	1.65(1.24-2.20)	Class III (moderate-quality)
ASA score≧3	10	13,049	0	0.415	0.474	1.34(1.19–1.51)	Class I (high-quality)
Emergent surgery	7	98,181	40	0.55	0.548	1.36(1.19-1.55)	Class I (high-quality)
IBD	3	93,663	63	0.262	0.296	2.12(1.24-3.61)	Class II (moderate-quality)
Wound classification	7	117,602	86	0.007	1.000	2.65(1.52-4.61)	Class III (moderate-quality)
Operative Time(≧180min)	6	5,842	58	0.195	0.133	1.88(1.49-2.36)	Class II (moderate-quality)
Cigarette smoking	6	206,303	64	0.129	0.260	1.38(1.14-1.67)	Class II (moderate-quality)
Open surgery	16	133,745	69	0.707	0.137	1.81(1.57-2.10)	Class II (moderate-quality)
Stoma creation	8	8,043	69	0.424	0.536	1.89(1.28-2.78)	Class II (moderate-quality)
Blood transfusion	5	6,279	74	0.567	0.806	2.03(1.34-3.06)	Class II (moderate-quality)
Respiratory comorbidity	3	112,896	76	0.079	0.296	2.62(0.84-8.13)	Class III (moderate-quality)
Neoplasm	5	91,881	81	0.466	0.462	1.24(0.58-2.26)	Class II (moderate-quality)
I-SSI							
Stoma	5	5,933	0	0.197	0.221	2.55(1.87-3.47)	Class I (high-quality)
D-SSI							
Obesity	3	7,272	17	0.002	0.296	1.63(1.48-1.80)	Class II (moderate-quality)
Blood transfusion	3	5,215	86	0.900	1.000	2.32(1.26-4.29)	Class II (moderate-quality)
ASA score≧3	3	5,157	0	0.821	1.000	1.14(0.90-1.46)	Class I (high-quality)
Open surgery	3	5,157	84	0.676	1.000	1.37(0.62-3.04)	Class II (moderate-quality)
Stoma creation	3	3,452	15	0.292	0.296	1.19(0.95-1.49)	Class I (high-quality)

Table 2. Risk factors of SSIs, I-SSI, and O-SSI in patients undergoing CRS.

https://doi.org/10.1371/journal.pone.0259107.t002

# **Risk factors of I-SSI and OS-SSI**

The risk factors for OS-SSI were also identified (Table 2). These risk factors included: obesity (RR = 1.63, 95% CI: 1.48–1.80, P < 0.00001); ASA score  $\ge 3$  (RR = 1.14, 95% CI: 0.90–1.46, P = 0.28); open surgery (RR = 1.37, 95% CI: 0.62–3.04, P = 0.44); stoma creation (RR = 1.19, 95% CI: 0.95–1.49, P = 0.12); and blood transfusion (RR = 2.32, 95% CI: 1.26–4.29, P = 0.007).

The risk factors for developing I-SSI were also explored. It was found that the risk factors of each study were not completely consistent (S3 Table). The classifications were not completely consistent even for the same indicators but still, the stoma creation was found to be a statistically significant risk factor for developing I-SSI (Table 2) (RR = 2.55, 95% CI: 1.87–3.47, P < 0.05).

# Sensitivity analyses

Further sensitivity analyses were conducted due to varying degrees of heterogeneities in the study. The merging direction of any risk factor was not significantly influenced using the fixed-effect models or random-effects (S4 Table). The pooled RR for the remaining studies remained unchanged in the above analysis after sequentially omitting any single study (S5 Table). Only the removal of Kwaan's [33] study from the analysis of respiratory comorbidity changed the overall conclusion (RR ranged from 2.62 (95% CI: 0.84–8.13) to 4.66 (95% CI: 1.46–14.89). Consequently, the results of this study regarding all the other risk factors might be stable.

### Assessment of publication bias

The funnel plot was used to qualitatively assess the publication bias (S1 Fig). There was a publication bias in some analyses due to asymmetric graphs.

The *P*-value, in the analysis of diabetes mellitus, was less than 0.05 based on the results of Egger's test, indicating a certain publication bias (Table 2). Accordingly, the funnel plot asymmetry was corrected using the trim and fill method. The five squared dots represented the effective quantities condition of included studies in the future and the corrected estimates of the intervention effects of 14 studies were 1.163 (95% CI = 0.901-1.501) (S2A Fig).

In the analysis of wound classification >2, the *P*-value was less than 0.05 based on the results of Egger's test, indicating a certain publication bias (Table 2). Accordingly, the funnel plot asymmetry was corrected using the trim and fill method. The four squared dots represented the effective quantities condition of included studies in the future and the corrected estimated of intervention effects of 11studies was 1.310 (95% CI = 0.790–2.173) (S2B Fig). Taken together, the relevant evidence should be continuously followed up and updated, eliminating the potential publication bias.

# Discussion

The factors in this study could be divided into two categories: modifiable and unmodifiable factors. The clinicians should monitor SSI earlier to achieve early prevention, intervention, and even effective treatment by targeting the unmodifiable factors. For the modifiable factors, the indicators can be adjusted throughout the perioperative period to further reduce the occurrence of SSI.

The commonly investigated unmodifiable risk factors, at least in the short term, including gender, obesity, ASA score, and primary disease diagnosis, can affect the incidence of SSI. Male sex is prone to develop SSI (RR = 1.30) due to abdominal visceral obesity. This might lead to a more complicated procedure with a longer surgical duration and incision, thereby increasing the SSI rate [50]. Obesity is commonly perceived to be associated with adverse outcomes, such as SSI [50]. It is worth noting that an appropriate definition of reasonable obesity might take into account the differences in visceral fats and ethnicity [50]. As reported, the BMI and SSI might be linearly correlated [51, 52]. Interestingly, the BMI <20 kg/m<sup>2</sup> is also an independent risk factor for SSI, reflecting the patient's malnutrition [31].

For unclear reasons, in this study, IBD but not cancer was strongly correlated with SSI. Increasing studies [51, 53] have found that the types of SSI were correlated with underlying disease diagnosis. For instance, the patients with diverticular developed more SSSI. Strikingly, patients with IBD had more DSSI and OS-SSI. The intrinsic mechanism for the increased correlation of disease diagnosis with SSI has not been emphasized yet in the medical literature. However, the SSI surveillance of CRS should take the surgical site and disease classification into account to more effectively identify the risk factors and reduce the occurrence of SSI. Meanwhile, more attention should be paid to the patients having one or more of the above risk factors in the postoperative follow-up period.

In this study, some modifiable factors also merit attention. The laparoscopic approach was correlated with the reduced occurrence of SSI. This has been already proven in previous studies [7, 54]. Notably, in this study, laparoscopic surgery could reduce the overall SSI rate but not OS-SSI. Unsurprisingly, this study showed that the long duration of surgery ( $\geq$ 180 min) was an independent predictor of SSI (RR = 1.88), which was consistent with a previous studies [31]. Moreover, the likelihood of SSI can be increased by increasing the duration of surgery [55]. The long-duration [56] is usually a reliable symbol of the complexity of the surgical procedure, with possible accidental local tissue injuries. A previous study [57] showed that the

in-hospital stoma formation was a risk factor for SSSI and DSSI but that study did not investigate OS-SSI. Similarly, this study found an 89% increase in the risk of SSI in patients having in-hospital stoma formation. The colostomy closure could lead to SSI in the patients having CRS [58, 59]. Perioperative blood transfusion is related to immunomodulation that could explain the increase in SSI rate [43]. Therefore, it is advised for the clinicians to focus on their surgical skills, shorten surgery duration, and reduce intraoperative blood loss and perioperative blood transfusion. In the meantime, the clinicians should suitably control the indicators of stoma formation and avoid unnecessary ones.

Cigarette smoking can delay wound healing, even for a minor and clean wound, thereby increasing the risk of SSI [8, 33, 36, 60]. This study found that the smokers had a 1.38-fold increased risk of developing SSI in comparison with the nonsmokers, which was consistent with the NNIS guidelines [58]. Smoking cessation instead of decreasing the level of smoking should be a routine as a part of perioperative management but there is often a time-limitation. Four weeks of abstinence from smoking before surgery might be appropriate [60]. A standard time to achieve smoking cessation as a part of perioperative management needs to be evaluated in more prospective studies.

The existence of underlying basic diseases can easily lead to the occurrence of SSI. Numerous studies [6, 61, 62] have confirmed that postoperative hyperglycemia is an independent risk factor for SSI and is also independent of diabetes. The uses of perioperative glycemic controls vary by country in the patients undergoing surgery. Many patients might adjust according to their actual situation. Further prospective studies are needed to verify the ideal perioperative glycemic regimens and optimal hemoglobin A1C target levels. Respiratory diseases are found to be associated with poor postoperative outcomes after CRS [63] but its correlation with SSI was not found in this study.

It is not appropriate to perform only preoperative mechanical bowel preparation in the patients undergoing CRS. Many antibiotic regimens have been studied to prevent SSI in patients undergoing CRS but there is no consensus on which antibiotic is the best [38]. Mechanical and oral antibiotic bowel preparation is widely used to reduce the risk of SSI after CRS [1, 64–66], which is well-accepted among many clinicians. Microorganisms in the intestinal lumen during surgery are still the potential infection sources of the surgical area; a joint plan is essential. On contrary, this view is suspected by more than 50% of American clinicians [67]. There are even calls for a reconsideration of this recommendation [68]. It should also be noted that the type of bowel preparation regimens cannot replace intravenous prophylactic antibiotics preoperatively. Many guidelines [69, 70] usually state that it should be administered within 60 min of an incision. The intra-operative re-dosing depends on the half-life of the drug and can be extended up to postoperative 24 h but this recommendation has not been tested rigorously. Owing to the lack of data, this aspect was not analyzed in this study.

There were different degrees of heterogeneities among the included studies, which were due to the differences in various clinical factors and parameters. First, the specific surgical procedures and the surgeon's surgical skills in each study were not completely consistent. Second, there were differences in cultural backgrounds. There were more or fewer differences in age, sex, education level, and national region among the patients in each trial. Thirdly, the methodological heterogeneity was caused by different studies. Nevertheless, this reflected a real-life situation and the results were trustworthy.

This study will be useful in future studies regarding SSI. This study aimed to provide data to solidify some risk factors but there are still some shortcomings. First, an important factor in preventing SSI is the surgeon's competence and skills [71], which is a variable factor that is difficult to quantify. The surgeon's experience could not be quantified in this study. Secondly, there might be inherent bias due to the nature of retrospective or prospective cohort studies.

Therefore, more studies and randomized controlled trials are still needed. Thirdly, the information of all the risk factors for I-SSI and OS-SSI could not be integrated due to the non-identical factor profiles of different studies. These differences showed that the two subtypes might have distinct pathogenesis and risk factors.

# Conclusions

The study showed that 12 factors (male sex, diabetes mellitus, obesity, ASA score  $\geq$ 3, cigarette smoking, wound classification >2, IBD, open surgery, stoma formation, emergent surgery, operative time  $\geq$ 180 min, and perioperative blood transfusion) were the significant risk factors for SSI. Moreover, two factors (obesity and blood transfusion) and one factor (stoma formation) were the significant risk factors for OS-SSI and I-SSI, respectively. A better understanding of these issues can lead to carrying out the precise intervention. There were some certain publication bias in 2 parameters based on asymmetric graphs, including diabetes mellitus and wound classification >2. Evidence should be continuously followed up and updated, eliminating the potential publication bias. In the future, additional high-level studies (such as well-designed randomized controlled trials or high-strength evidence according to the different grading systems) are needed to verify these results.

# Supporting information

**S1 Table. Detailed search strategies for each database.** (DOC)

**S2** Table. Quality assessment of included studies using NOS. (DOC)

**S3 Table. Risk factor of I-SSI in patients undergoing CRS.** (DOC)

**S4** Table. Sensitivity analysis of the meta-analysis. (DOC)

**S5** Table. Sensitivity analysis of the meta-analysis. (DOC)

S1 Fig. The publication bias of the relevant factors of SSIs (A: Male sex; B: Obesity; C: Diabetes mellitus; D: ASA score≥3; E: Emergent surgery; F: Wound classification> 2; G: Operative time ≥180 min; H: Cigarette smoking; I: Open surgery; J: Stoma formation). (DOC)

**S2 Fig. The trim and fill graphs.** (A: Diabetes mellitus; B: wound classification>2). (DOC)

**S1 Checklist.** (PDF)

# **Author Contributions**

Conceptualization: ZhaoHui Xu, Hui Qu, ZeZhong Gong, George Kanani, Xin Chen.

Data curation: ZhaoHui Xu, Hui Qu.

**Formal analysis:** ZhaoHui Xu, Hui Qu, ZeZhong Gong, Fan Zhang, YanYing Ren, Shuai Shao, XiaoLiang Chen.

Investigation: ZhaoHui Xu.

Methodology: ZhaoHui Xu, Hui Qu.

Project administration: ZhaoHui Xu, George Kanani.

Software: ZhaoHui Xu.

Supervision: ZhaoHui Xu, Fan Zhang.

Validation: ZhaoHui Xu.

Visualization: ZhaoHui Xu.

- Writing original draft: ZhaoHui Xu, Hui Qu, ZeZhong Gong, George Kanani, Fan Zhang, YanYing Ren, Shuai Shao, XiaoLiang Chen, Xin Chen.
- Writing review & editing: ZhaoHui Xu, Hui Qu, ZeZhong Gong, George Kanani, Fan Zhang, YanYing Ren, Shuai Shao, XiaoLiang Chen, Xin Chen.

#### References

- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infection control and hospital epidemiology. 1999; 20(4):250–278. https://doi.org/10.1086/501620 PMID: 10219875
- Weiss CA 3rd, Statz CL, Dahms RA, Remucal MJ, Dunn DL, Beilman GJ. Six years of surgical wound infection surveillance at a tertiary care center: review of the microbiologic and epidemiological aspects of 20,007 wounds. Archives of surgery (Chicago, III: 1960). 1999; 134(10):1041–1048. https://doi.org/ 10.1001/archsurg.134.10.1041 PMID: 10522843
- 3. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infection control and hospital epidemiology. 1999; 20(11):725–730. https://doi.org/10.1086/501572 PMID: 10580621
- Anthony T, Long J, Hynan LS, S GA Jr, Nwariaku F, Huth J, et al. Surgical complications exert a lasting effect on disease-specific health-related quality of life for patients with colorectal cancer. Surgery. 2003; 134(2):119–125. https://doi.org/10.1067/msy.2003.212 PMID: 12947307
- Hubner M, Diana M, Zanetti G, Eisenring MC, Demartines N, Troillet N. Surgical site infections in colon surgery: the patient, the procedure, the hospital, and the surgeon. Archives of surgery (Chicago, Ill: 1960). 2011; 146(11):1240–1245. https://doi.org/10.1001/archsurg.2011.176 PMID: 21768407
- Ata A, Valerian BT, Lee EC, Bestle SL, Elmendorf SL, Stain SC. The effect of diabetes mellitus on surgical site infections after colorectal and noncolorectal general surgical operations. The American surgeon. 2010; 76(7):697–702. PMID: 20698373
- Kiran RP, El-Gazzaz GH, Vogel JD, Remzi FH. Laparoscopic approach significantly reduces surgical site infections after colorectal surgery: data from national surgical quality improvement program. Journal of the American College of Surgeons. 2010; 211(2):232–238. <u>https://doi.org/10.1016/j.jamcollsurg</u>. 2010.03.028 PMID: 20670861
- Nasser H, Ivanics T, Leonard-Murali S, Stefanou A. Risk Factors for Surgical Site Infection After Laparoscopic Colectomy: An NSQIP Database Analysis. Journal of Surgical Research. 2020; 249:25–33. https://doi.org/10.1016/j.jss.2019.12.021 PMID: 31918327
- Tang R, Chen HH, Wang YL, Changchien CR, Chen JS, Hsu KC, et al. Risk factors for surgical site infection after elective resection of the colon and rectum: A single-center prospective study of 2,809 consecutive patients. Annals of surgery. 2001; 234(2):181–189. <u>https://doi.org/10.1097/00000658-</u> 200108000-00007 PMID: 11505063
- Xu Z, Qu H, Kanani G, Guo Z, Ren Y, Chen X. Update on risk factors of surgical site infection in colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2020; 35(12):2147–2156. https://doi.org/10.1007/s00384-020-03706-8 PMID: 32748113
- Hang C, Clymer JW, Brian PHC, Behnam S, Ferko NC, Cameron CG, et al. Prolonged operative duration is associated with complications: a systematic review and meta-analysis. Journal of Surgical Research. 2018; 229:134–144. https://doi.org/10.1016/j.jss.2018.03.022 PMID: 29936980
- Andreas Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology. 2010; 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370

- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA: The Journal of the American Medical Association. 2000; 283(15):2008–2012. https://doi.org/10.1001/jama.283.15.2008 PMID: 10789670
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009; 18(3):e123. <u>https://doi.org/10.1371/journal.pmed.</u> 1000097 PMID: 19621072
- Mei ZB, Wang QM, Zhang Y, Liu P, Ge MJ, Du PX, et al. Risk Factors for Recurrence after Anal Fistula Surgery: A Meta-analysis. Int J Surg.2019; 69:153–164. <u>https://doi.org/10.1016/j.ijsu.2019.08.003</u> PMID: 31400504
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring Inconsistency In Meta-Analyses. BMJ: British Medical Journal. 2003; 327(7414):557–560. <u>https://doi.org/10.1136/bmj.327.7414.557</u> PMID: 12958120
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088–1101. PMID: 7786990
- Egger M, Smith GD, Schneider M, Minder C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ: British Medical Journal. 1997; 315(7109):629–634. <u>https://doi.org/10.1136/bmj.315.7109</u>. 629 PMID: 9310563
- Imai E, Ueda M, Kanao K, Kubota T, Hasegawa H, Omae K, et al. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery. American journal of infection control. 2008; 36(10):727–731. <u>https://doi.org/10.1016/j.ajic.2007.12.011</u> PMID: 18834730
- Wick EC, Hirose K, Shore AD, Clark JM, Gearhart SL, Efron J, et al. Surgical site infections and cost in obese patients undergoing colorectal surgery. Archives of Surgery. 2011; 146(9):1068–1072. https:// doi.org/10.1001/archsurg.2011.117 PMID: 21576597
- Biondo S, Kreisler E, Fraccalvieri D, Basany EE, Codina-Cazador A, Ortiz H. Risk factors for surgical site infection after elective resection for rectal cancer. A multivariate analysis on 2131 patients. Colorectal Disease. 2012; 14(3):e95–e102. <u>https://doi.org/10.1111/j.1463-1318.2011.02798.x</u> PMID: 21883813
- Tserenpuntsag B, Haley V, Van Antwerpen C, Doughty D, Gase KA, Hazamy PA, et al. Surgical site infection risk factors identified for patients undergoing colon procedures, New York State 2009–2010. Infection control and hospital epidemiology. 2014; 35(8):1006–1012. <u>https://doi.org/10.1086/677156</u> PMID: 25026617
- Poeran J, Wasserman I, Zubizarreta N, Mazumdar M. Characteristics of Antibiotic Prophylaxis and Risk of Surgical Site Infections in Open Colectomies. Diseases of the colon and rectum. 2016; 59(8):733– 742. https://doi.org/10.1097/DCR.0000000000633 PMID: 27384091
- Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2017; 31(4):1923– 1929. https://doi.org/10.1007/s00464-016-5195-0 PMID: 27734204
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 2000; 894(1):18–30. PMID: 11234459
- Bot J, Piessen G, Robb WB, Roger V, Mariette C. Advanced tumor stage is an independent risk factor of postoperative infectious complications after colorectal surgery: Arguments from a case-matched series. Diseases of the colon and rectum. 2013; 56(5):568–576. <u>https://doi.org/10.1097/DCR.</u> 0b013e318282e790 PMID: 23575395
- Hibbert D, Abduljabbar AS, Alhomoud SJ, Ashari LH, Alsanea N. Risk factors for abdominal incision infection after colorectal surgery in a Saudi Arabian population: The method of surveillance matters. Surgical infections. 2015; 16(3):254–262. https://doi.org/10.1089/sur.2013.208 PMID: 25844951
- 29. Mik M, Berut M, Trzcinski R, Dziki L, Buczynski J, Dziki A. Preoperative oral antibiotics reduce infections after colorectal cancer surgery. Langenbeck's archives of surgery / deutsche gesellschaft fur chirurgie. 2016; 401(8):1153-1162. https://doi.org/10.1007/s00423-016-1513-1 PMID: 27650707
- 30. Cima RR, Bergquist JR, Hanson KT, Thiels CA, Habermann EB. Outcomes are Local: Patient, Disease, and Procedure-Specific Risk Factors for Colorectal Surgical Site Infections from a Single Institution. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2017; 21(7):1142–1152. https://doi.org/10.1007/s11605-017-3430-1 PMID: 28470562
- Bislenghi G, Vanhaverbeke A, Fieuws S, Overstraeten AdBv, D'Hoore A, Schuermans A, et al. Risk factors for surgical site infection after colorectal resection: a prospective single centre study An analysis on

287 consecutive elective and urgent procedures within an institutional quality improvement project. Acta chirurgica Belgica. 2019:1–24. https://doi.org/10.1080/00015458.2019.1675969 PMID: 31577178

- Ghuman A, Brown C, Karimuddin A, Raval M, Phang T. Surgical site infection rates following implementation of a colorectal closure bundle in elective colorectal surgeries. Diseases of the colon and rectum. 2015; 58(5):133–135. https://doi.org/10.1097/DCR.00000000000455 PMID: 26445181
- 33. Kwaan MR, Melton GB, Madoff RD, Chipman JG. Abdominoperineal Resection, Pelvic Exenteration, and Additional Organ Resection Increase the Risk of Surgical Site Infection after Elective Colorectal Surgery: An American College of Surgeons National Surgical Quality Improvement Program Analysis. Surgical infections. 2015; 16(6):675–683. https://doi.org/10.1089/sur.2014.144 PMID: 26237302
- Park YY, Kim CW, Park SJ, Lee Y, Lee JJ, Lee HO, et al. Influence of shorter duration of prophylactic antibiotic use on the incidence of surgical site infection following colorectal cancer surgery. Annals of coloproctology. 2015; 31(6):235–242. https://doi.org/10.3393/ac.2015.31.6.235 PMID: 26817019
- Silvestri M, Dobrinja C, Scomersi S, Giudici, Turoldo, Princic E, et al. Modifiable and non-modifiable risk factors for surgical site infection after colorectal surgery: a single-center experience. Surgery today. 2018; 48(3):338–345. https://doi.org/10.1007/s00595-017-1590-y PMID: 28948367
- Guzman-Pruneda FA, Husain SG, Jones CD, Beal W, Porter, Grove M, et al. Compliance with preoperative care measures reduces surgical site infection after colorectal operation. Journal of surgical oncology. 2019; 119(4):497–502. https://doi.org/10.1002/jso.25346 PMID: 30582613
- Uchino M, Ikeuchi H, Tsuchida T, Nakajima K, Tomita N, Takesue Y. Surgical site infection following surgery for inflammatory bowel disease in patients with clean-contaminated wounds. World journal of surgery. 2009; 33(5):1042–1048. https://doi.org/10.1007/s00268-009-9934-4 PMID: 19198930
- Ho VP, Barie PS, Stein SL, Trencheva K, Milsom JW, Lee SW, et al. Antibiotic regimen and the timing of prophylaxis are important for reducing surgical site infection after elective abdominal colorectal surgery. Surgical infections. 2011; 12(4):255–260. https://doi.org/10.1089/sur.2010.073 PMID: 21790479
- Watanabe M, Suzuki H, Nomura S, Hanawa H, Chihara N, Mizutani S, et al. Performance Assessment of the Risk Index Category for Surgical Site Infection after Colorectal Surgery. Surgical infections. 2015; 16(1):84–89. https://doi.org/10.1089/sur.2013.260 PMID: 25650526
- Bert F, Giacomelli S, Amprino V, Pieve G, Ceresetti D, Testa M et al. The "bundle" approach to reduce the surgical site infection rate. Journal of evaluation in clinical practice. 2017; 23(3):642–647. <u>https:// doi.org/10.1111/jep.12694</u> PMID: 28145067
- Blumetti J, Luu M, Sarosi G, Hartless K, McFarlin J, Parker B, et al. Surgical site infections after colorectal surgery: Do risk factors vary depending on the type of infection considered? Surgery. 2007; 142 (5):704–711. https://doi.org/10.1016/j.surg.2007.05.012 PMID: 17981191
- Hennessey DB, Burke JP, Ni-Dhonochu T, Shields C, Winter DC, Mealy K. Risk factors for surgical site infection following colorectal resection: a multi-institutional study. International journal of colorectal disease. 2016; 31(2):267–271. https://doi.org/10.1007/s00384-015-2413-5 PMID: 26507963
- Colas-Ruiz E, Del-Moral-Luque JA, Gil-Yonte P, Fernández-Cebriá n M, Alonso-García M, Villar-Del-Campo MC, et al. Incidence of surgical site infection and risk factors in rectal surgery: A prospective cohort study. Cirugia espanola. 2018; 96(10):640–647. https://doi.org/10.1016/j.ciresp.2018.06.007 PMID: 30093098
- 44. Kwaan MR, Sirany AM, Rothenberger DA, Madoff RD. Abdominal wall thickness: is it associated with superficial and deep incisional surgical site infection after colorectal surgery? Surgical infections. 2013; 14(4):363–368. https://doi.org/10.1089/sur.2012.109 PMID: 23676120
- 45. Itatsu K, Sugawara G, Kaneoka Y, Kato T, Takeuchi E, Kanai M, et al. Risk factors for incisional surgical site infections in elective surgery for colorectal cancer: Focus on intraoperative meticulous wound management. Surgery today. 2014; 44(7):1242–1252. https://doi.org/10.1007/s00595-013-0677-3 PMID: 23913010
- Olmez T, Karakose E, Keklikkiran ZZ, Ofluoglu B, Bas, Uzun O, et al. Relationship between Sarcopenia and Surgical Site Infection in Patients Undergoing Colorectal Cancer Surgical Procedures. Surgical infections. 2019. https://doi.org/10.1089/sur.2019.285 PMID: 31859591
- Nakamura T, Mitomi H, Ihara A, Onozato W, Sato T, Ozawa H, et al. Risk factors for wound infection after surgery for colorectal cancer. World journal of surgery. 2008; 32(6):1138–1141. <u>https://doi.org/10.1007/s00268-008-9528-6</u> PMID: 18404288
- Poon JT, Law WL, Wong IW, Ching PT, Wong LM, Fan JKM, et al. Impact of laparoscopic colorectal resection on surgical site infection. Annals of surgery. 2009; 249(1):77–81. <u>https://doi.org/10.1097/SLA.0b013e31819279e3</u> PMID: 19106679
- 49. Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, et al. Risk factors for surgical site infection and association with infliximab administration during surgery for Crohn's disease. Diseases of the colon and rectum. 2013; 56(10):1156–1165. https://doi.org/10.1097/DCR.0b013e31829f682c PMID: 24022533

- Makino T, Shukla PJ, Rubino F, Milsom JW. The Impact of Obesity on Perioperative Outcomes After Laparoscopic Colorectal Resection. Annals of surgery. 2012; 255(2):228–236. https://doi.org/10.1097/ SLA.0b013e31823dcbf7 PMID: 22190113
- Bhakta A, Tafen M, Glotzer O, Ata A, Chismark AD, Valerian BT, et al. Increased Incidence of Surgical Site Infection in IBD Patients. Diseases of the colon and rectum. 2016; 59(4):316–322. https://doi.org/ 10.1097/DCR.00000000000550 PMID: 26953990
- Gurunathan U, Ramsay S, Mitrić G, Way M, Wockner L, Myles P. Association Between Obesity and Wound Infection Following Colorectal Surgery: Systematic Review and Meta-Analysis. Journal of Gastrointestinal Surgery. 2017; 21(10):1700–1712. <u>https://doi.org/10.1007/s11605-017-3494-y</u> PMID: 28785932
- Pendlimari R, Cima RR, Wolff BG, Pemberton JH, Huebner M. Diagnoses Influence Surgical Site Infections (SSI) in Colorectal Surgery: A Must Consideration for SSI Reporting Programs? Journal of the American College of Surgeons. 2012; 214(4):574–580. https://doi.org/10.1016/j.jamcollsurg.2011.12. 023 PMID: 22321525
- 54. Gandaglia G, Ghani KR, Sood A, Meyers R, Sammon D, Schmid M, et al. Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database. JAMA surgery. 2014; 149(10):1039–1044. https://doi.org/10.1001/jamasurg.2014.292 PMID: 25143176
- Cheng H, Chen PH, Soleas IM, Ferko NC, Cameron CG, Hinoul P. Prolonged Operative Duration Increases Risk of Surgical Site Infections: A Systematic Review. Surgical infections. 2017; 18(6):722– 735. https://doi.org/10.1089/sur.2017.089 PMID: 28832271
- 56. Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. The American journal of medicine. 1991; 91(3b):152s–157s. https://doi.org/10.1016/ 0002-9343(91)90361-z PMID: 1656747
- Ricciardi R, Roberts PL, Hall JF, Read TE, Marcello PW. What Is the Effect of Stoma Construction on Surgical Site Infection After Colorectal Surgery? Journal of Gastrointestinal Surgery. 2014; 18(4):789– 795. https://doi.org/10.1007/s11605-013-2439-3 PMID: 24408182
- Konishi T, Watanabe T, Kishimoto J, Nagawa H. Elective colon and rectal surgery differ in risk factors for wound infection Results of prospective surveillance. Annals of surgery. 2006; 244(244):758–763. https://doi.org/10.1097/01.sla.0000219017.78611.49 PMID: 17060769
- Hackam D, Rotstein O. Stoma closure and wound infection: an evaluation of risk factors. Canadian Journal of Surgery Journal Canadien De Chirurgie. 1995; 38(2):144–148. PMID: 7728668
- Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Annals of surgery. 2003; 238(1):1–5. <u>https://doi.org/10.1097/01.SLA.</u> 0000074980.39700.31 PMID: 12832959
- Kiran RP, Turina M, Hammel J, Fazio V. The clinical significance of an elevated postoperative glucose value in nondiabetic patients after colorectal surgery: evidence for the need for tight glucose control? Annals of surgery. 2013; 258(4):599–604; discussion 604–595. <u>https://doi.org/10.1097/SLA.</u> 0b013e3182a501e3 PMID: 23979274
- Kwon S, Thompson RE, Dellinger P, Rogers T, D F. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Annals of surgery. 2013; 172(2):274. https://doi.org/10.1097/SLA.0b013e31827b6bbc PMID: 23235393
- 63. Baré M, Montón C, Mora L, Redondo, Pont, Escobar A, et al. COPD is a clear risk factor for increased use of resources and adverse outcomes in patients undergoing intervention for colorectal cancer: a nationwide study in Spain. International Journal of Chronic Obstructive Pulmonary Disease. 2017; 12:1233–1241. https://doi.org/10.2147/COPD.S130377 PMID: 28461746
- Koller SE, Bauer KW, Egleston BL, Smith, Philp M, Ross HM, et al. Comparative Effectiveness and Risks of Bowel Preparation Before Elective Colorectal Surgery. Annals of surgery. 2017; 267(4):734– 742. https://doi.org/10.1097/SLA.0000000002159 PMID: 28151800
- Klinger AL, Green H, Monlezun DJ, Beck, Kann, Vargas HD, et al. The Role of Bowel Preparation in Colorectal Surgery: Results of the 2012–2015 ACS-NSQIP Data. Annals of surgery. 2019; 269(4):671– 677. https://doi.org/10.1097/SLA.00000000002568 PMID: 29064902
- 66. Migaly J, Bafford AC, Francone TD, Gaertner B, Eskicioglu, Bordeianou L, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Use of Bowel Preparation in Elective Colon and Rectal Surgery. Diseases of the colon and rectum. 2019; 62(1):3–8. <u>https://doi.org/10.1097/DCR.00000000001238 PMID: 30531263</u>
- Zmora O, Wexner SD, Hajjar L, Park T, Weiss EG. Trends in preparation for colorectal surgery: Survey of the members of the American Society of Colon and Rectal Surgeons. J Am Surg. 2003; 69(2):150– 154. PMID: 12641357

- Laura K, Taru L, Selja K, Rasilainen, Klintrup, Ehrlich A, et al. Mechanical and oral antibiotic bowel preparation versus no bowel preparation for elective colectomy (MOBILE): a multicentre, randomised, parallel, single-blinded trial. The Lancet. 2019; 394(10201):840–848. <a href="https://doi.org/10.1016/S0140-6736">https://doi.org/10.1016/S0140-6736</a> (19)31269-3 PMID: 31402112
- 69. Fry DE. Preventive Systemic Antibiotics in Colorectal Surgery. Surgical infections. 2008; 9(6):547–552. https://doi.org/10.1089/sur.2008.9956 PMID: 19216664
- 70. Steinberg JP, Braun BI, Hellinger WC, Kusek L, Bozikis MR, Bush AJ, et al. Timing of Antimicrobial Prophylaxis and the Risk of Surgical Site Infections. Annals of surgery. 2009; 250(1):10–16. https://doi.org/ 10.1097/SLA.0b013e3181ad5fca PMID: 19561486
- Mchugh SM, Hill ADK, Humphreys H. Intraoperative technique as a factor in the prevention of surgical site infection. Journal of Hospital Infection. 2011; 78(1):1–4. <u>https://doi.org/10.1016/j.jhin.2011.01.011</u> PMID: 21367488